Text Size
7 studies found for:    "Hyperlipoproteinemia type 1"

Modify this search | How to Use Search Results

Show Display Options
Rank Status Study
1 Recruiting Extension to a Randomized, Double-blind, Placebo Controlled Study of LCQ908 in Subjects With Familial Chylomicronemia Syndrome.
Condition: Familial Chylomicronemia Syndrome (FCS) (HLP Type I)
Intervention: Drug: LCQ908
2 Recruiting A Randomized, Double-blind, Placebo Controlled Study to Assess Efficacy, Safety and Tolerability of LCQ908 in Subjects With Familial Chylomicronemia Syndrome
Condition: Familial Chylomicronemia Syndrome (FCS)
Interventions: Drug: LCQ908;   Drug: Placebo
3 Suspended Duration of Effect of Alipogene Tiparvovec Treatment, Which Was Administered in Other Studies
Condition: Hyperlipoproteinemia Type I
Intervention:
4 Active, not recruiting Safety and Efficacy in LPL-Deficient Subjects of AMT-011, an Adeno-Associated Viral Vector Expressing Human Lipoprotein Lipase [S447X]
Condition: Familial Lipoprotein Lipase Deficiency
Interventions: Genetic: Alipogene Tiparvovec (AMT-011), Human LPL [S447X];   Drug: Mycophenolate mofetil;   Drug: cyclosporine
5 Completed Efficacy and Safety of Human Lipoprotein Lipase (LPL)[S447X] Expressed by an Adeno-Associated Viral Vector in LPL-deficient Subjects
Condition: Familial Lipoprotein Lipase Deficiency
Interventions: Genetic: Alipogene Tiparvovec (AMT-011), Human LPL [S447X];   Drug: mycophenolate mofetil;   Drug: cyclosporine;   Drug: methylprednisolone
6 Enrolling by invitation Study to Re-assess and Re-confirm Data Previously Recorded About the Incidence and Severity of Acute Abdominal "Pancreatitis" Episodes in Lipoprotein Lipase Deficient (LPLD) Subjects Previously Enrolled on AMT Clinical Studies
Condition: Lipoprotein Lipase Deficiency
Intervention:
7 Completed Safety, Tolerability,Pharmacokinetics(PK)and Pharmacodynamics(PD)Assessment of LCQ908 in Patients With Severe Hypertriglyceridemia
Condition: Hyperlipoproteinemia
Interventions: Drug: LCQ908;   Drug: Placebo
To Top

† Indicates status has not been verified in more than two years